Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.54 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.50 |
| ▸ | CSF1R | P07333 | 8/20 | 0.46 |
| ▸ | KDR | P35968 | 8/20 | 0.46 |
| ▸ | KIT | P10721 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | NRAS | P01111 | 2/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24975706 | 1.00 | FLT3 (0.54) | FLT3IRAK4MAPK8CSF1RKDR | |
| SCHEMBL31557817 | 0.92 | FLT3 (0.59) | FLT3IRAK4MAPK8CSF1RKDR | |
| SCHEMBL24975666 | 0.92 | FLT3 (0.59) | FLT3IRAK4MAPK8CSF1RKDR | |
| SCHEMBL24975899 | 0.91 | MAPK8 (0.48) | FLT3IRAK4MAPK8CSF1RKDR | |
| SCHEMBL30621279 | 0.91 | MAPK8 (0.48) | FLT3IRAK4MAPK8CSF1RKDR | |
| SCHEMBL24976617 | 0.90 | MAPK8 (0.49) | FLT3IRAK4MAPK8CSF1RKDR | |
| SCHEMBL31557792 | 0.90 | MAPK8 (0.49) | FLT3IRAK4MAPK8CSF1RKDR | |
| SCHEMBL31557801 | 0.90 | MAPK8 (0.49) | FLT3IRAK4MAPK8CSF1RKDR | |
| SCHEMBL24975708 | 0.90 | MAPK8 (0.49) | FLT3IRAK4MAPK8CSF1RKDR | |
| SCHEMBL24975942 | 0.88 | MAPK8 (0.47) | FLT3IRAK4MAPK8CSF1RKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154144-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDRENS HOSPITAL MED CT (US) | 2025-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154144-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK3 | FLT3 1/4885IRAK4 5/4885MAPK8 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.